A retrospective study assessing the efficacy of IV lacosamide versus levetiracetam as an early therapeutic treatment for Non-Convulsive Status Epilepticus
Latest Information Update: 09 Jun 2021
Price :
$35 *
At a glance
- Drugs Lacosamide (Primary) ; Levetiracetam (Primary)
- Indications Status epilepticus
- Focus Therapeutic Use
- 09 Jun 2021 New trial record
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology